The Russian Direct Investment Fund (RDIF) has reported positive real-world data of the Ministry of the Health of the Republic of San Marino on the Sputnik V Covid-19 vaccine’s long-term efficacy.
Data showed that the vaccine had an 80% efficacy against Covid-19 from six to eight months following the second dose.
Based on an established and well-studied platform of human adenoviral vectors, the vaccine utilises two different vectors for the two shots for vaccination.
This approach aids in offering immunity for an extended period as against the vaccines, which utilise the same delivery mechanism for both doses.
RDIF noted that the vaccine efficacy for six to eight months is greater than the efficacy of Covid-19 mRNA vaccines, potentially due to an extended antibody and T-cell response.
The Health Ministry of Russia is set to register the Sputnik V vaccine for adolescents in the age group of 12 to 17 years, RDIF added.
Separately, the RDIF has announced plans to introduce a single shot Sputnik Light Covid-19 vaccine in India by next month, ANI reported.
Sputnik Light is based on the primary component of Sputnik V, a recombinant human adenovirus serotype number 26 (rAd26).
The news agency quoted RDIF CEO Kirill Dmitriev as saying: “We are hopeful for the launch of Sputnik Light in India in December and we are working very well with Indian institutes.”
“We have Serum Institute as our production partner in India, and we believe that Sputnik Light will play a big role in the Indian vaccination campaign.”
In several combination trials in Argentina and Azerbaijan, a booster dose of Sputnik Light elicited an immune response greater than two shots of the same vaccine.
Meanwhile, Russia also announced plans to export a nasal form of its Sputnik vaccine against Covid-19, Reuters reported.
The Emergency Use Listing (EUL) process of Sputnik V is still on hold by the World Health Organization (WHO) due to some legal procedures and missing data.